ArticleDrug delivery and translational research2022
Topical and transdermal delivery with diseased human skin: passive and iontophoretic delivery of hydrocortisone into psoriatic and eczematous skin.
Article in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Pharmacokinetics of Moxidectin in Bare-Nosed Wombats (Vombatus ursinus) After Intravenous, Sub-Cutaneous and Transdermal Administration.Journal of veterinary pharmacology and therapeutics · 2026Article
- Iontophoresis-assisted transdermal drug delivery for the treatment of inflammatory dermatoses: A review.Journal of pharmaceutical analysis · 2026Review
- Transdermal Drug Delivery Systems in Atopic Dermatitis: A Review of Vehicle Innovation and Skin Barrier Challenges.Cureus · 2025Review
- Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases.Pharmaceutics · 2025Review
- Strategic advances in liposomes technology: translational paradigm in transdermal delivery for skin dermatosis.Journal of nanobiotechnology · 2025Review
- A comprehensive classification and analysis of oily sensitive facial skin: a cross-sectional study of young Chinese women.Scientific reports · 2025Article
- Hypothesis: platelet-rich plasma as an adjunct therapy for eczema targeting inflammation, skin barrier repair, and chronic recurrence.Frontiers in immunology · 2025Article
- Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery.Pharmaceutics · 2024Review
- The Necessity to Investigate In Vivo Fate of Nanoparticle-Loaded Dissolving Microneedles.Pharmaceutics · 2024Review
- Novel Vehicles For Drug Delivery in Atopic Dermatitis: A Narrative Review.Dermatology practical & conceptual · 2023Review
- Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System.Pharmaceutics · 2023Review
- Review
- Microneedle Mediated Iontophoretic Delivery of Tofacitinib Citrate.Pharmaceutical research · 2023Article
- Bibliometric analysis and visualization of transdermal drug delivery research in the last decade: global research trends and hotspots.Frontiers in pharmacology · 2023Article
- Synthesis and Characterization of Chitosan-Decorated Nanoemulsion Gel of 5-Fluorouracil for Topical Delivery.Gels (Basel, Switzerland) · 2022Article
- Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin.Frontiers in chemistry · 2022Article
- Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Psoriasis and atopic dermatitis (eczema) are both common immune-mediated inflammatory skin diseases associated with changes in skin's stratum corneum lipid structure and barrier functionality. The present study aimed to investigate healthy, eczematous, and psoriatic excised human tissue for the effect of non-infectious skin diseases on skin characteristics (surface color, pH, transepidermal water loss, electrical resistance, and histology), as well as on permeation and retention profile of hydrocortisone. Further, differences in percutaneous absorption on application of iontophoresis on healthy and diseased skin were also investigated. Measurements of transepidermal water loss and electrical resistance showed a significant difference in psoriasis skin samples indicating a damaged barrier function. In vitro permeation studies on full-thickness human skin using vertical diffusion cells further confirmed these results as the drug amount retained in the psoriatic tissue was significantly higher when compared with the other groups. Despite no significant difference, the presence of the drug in the receptor chamber in both diseased groups can be concerning as it suggests the increased possibility of systemic absorption and adverse reactions associated with it in the use of topical corticosteroids. Application of anodal iontophoresis resulted in greater distribution of hydrocortisone into deeper layers of skin and the receptor chamber, in comparison to passive permeation. However, no significant differences were observed due to the healthy or diseased condition of skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.